Regeneron Pharmaceuticals, Inc. splits its revenue into 5 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Collaboration Revenue at $3.0 billion, 59% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
16,896
|
5,116
|
4,291
|
3,605
|
3,884
|
3,754
|
3,676
|
3,029
|
3,789
|
| Collaboration Revenue |
—
|
3,000
+52.4%
share 58.7%
|
2,455
+31.9%
share 57.2%
|
1,900
+24.1%
share 52.7%
|
1,971
+22.7%
share 50.7%
|
1,968
share 52.4%
|
1,861
share 50.6%
|
1,531
share 50.6%
|
1,607
share 42.4%
|
| Product |
—
|
1,805
+13.7%
share 35.3%
|
1,642
+0.7%
share 38.3%
|
1,534
+8.4%
share 42.6%
|
1,675
-16.4%
share 43.1%
|
1,588
share 42.3%
|
1,631
share 44.4%
|
1,416
share 46.7%
|
2,003
share 52.9%
|
| Product And Service Other |
—
|
310
+56.4%
share 6.1%
|
193
+5.1%
share 4.5%
|
171
+109.0%
share 4.7%
|
239
+33.0%
share 6.1%
|
198
share 5.3%
|
184
share 5.0%
|
82
share 2.7%
|
179
share 4.7%
|
| Lynozyfic |
—
|
19
+2275.0%
share 0.4%
|
16
share 0.4%
|
11
share 0.3%
|
—
|
1
share 0.0%
|
—
|
—
|
—
|
| Other Products |
—
|
1
+0.0%
share 0.0%
|
—
|
31
share 0.9%
|
9
share 0.2%
|
1
share 0.0%
|
—
|
—
|
—
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- REGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NY
- Headquarters
- Tarrytown, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 872589
- Former names
- REGENERON PHARMACEUTICALS INC (until Jun 19, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.